论文部分内容阅读
骨肉瘤肺转移患者治疗效果差,总生存率仅20%～25%。过去30年中,尽管尝试多种化疗方案仍未能明显提高患者生存率,开展新的治疗方案迫在眉睫。MD Anderson癌症中心前期曾报告,Fas通路在骨肉瘤患者的肺转移瘤生长中扮演重要角色。而肺组织是人体少数持续表达Fas配体(FasL)的器官。肿瘤细胞表面Fas受体结合FasL及其他分子最终形成死亡诱导信号复合物,诱导细胞的凋亡。组蛋白脱乙酰酶抑制剂SNDX-275已被证实能够提高FasL表达
Patients with osteosarcoma lung metastasis poor treatment, the overall survival rate of only 20% to 25%. Over the past 30 years, although trying multiple chemotherapy regimens has not significantly improved patient survival, new treatment options are imminent. MD Anderson Cancer Center has previously reported that Fas pathway plays an important role in the growth of lung metastases in patients with osteosarcoma. Lung tissue is an organ that continuously expresses Fas ligand (FasL) in the human body. Tumor cell surface Fas receptor binding FasL and other molecules eventually form death-inducing signaling complex, inducing cell apoptosis. Histone deacetylase inhibitor SNDX-275 has been shown to enhance FasL expression